• Facebook
  • X
  • Instagram
MYELOMA360
  • Home
  • MYInsights
  • MYBoard
  • Strategy & Consulting
Select Page

An Over-the-Counter Evidence-Based Approach to Reducing the Risk of Antibiotic-Associated Diarrhea

by MM360 Staff | May 22, 2025 | Myeloma News

Source: Pharmacy Times articles Post Content Read More

Navigating the Complexities of the Cell and Gene Therapy Landscape: Insights From the 2025 Advanced Therapies Report

by MM360 Staff | May 22, 2025 | Myeloma News

Source: Pharmacy Times articles The report highlights the expanding role of pharmacists in navigating regulatory, financial, logistical, and clinical complexities to ensure safe, equitable, and effective delivery of cell and gene therapies amid a rapidly growing and...

Additional Dose of IVIG Provides Positive Therapeutic Effect in Patients With Infliximab-Refractory Kawasaki Disease

by MM360 Staff | May 22, 2025 | Myeloma News

Source: Pharmacy Times articles Additional intravenous immunoglobulin (IVIG) treatment shows promise for Kawasaki disease patients resistant to infliximab, potentially matching the efficacy of second IVIG doses in patients resistant to IVIG. Read More

Sogroya Observed as Efficacious and Well-Tolerated in Children With Growth Disorders

by MM360 Staff | May 22, 2025 | Myeloma News

Source: Pharmacy Times articles The phase 3 REAL8 trial shows once-weekly Sogroya effectively improves growth in children with growth disorders, offering a promising alternative to daily injections. Read More

Zepbound From Eli Lilly and Company

by MM360 Staff | May 22, 2025 | Myeloma News

Source: Pharmacy Times articles Post Content Read More

Pharmacists Can Improve Patient Safety With Behavior Change Communication

by MM360 Staff | May 22, 2025 | Myeloma News

Source: Pharmacy Times articles Counseling for behavior change helps patients understand the importance of their medications and make positive changes. Read More
« Older Entries
Next Entries »

Recent Content

  • Prognostic and clinicopathological value of prognostic nutritional index in patients with multiple myeloma: a meta-analysis
  • Daratumumab plus lenalidomide maintenance in newly diagnosed multiple myeloma after transplant: AURIGA subgroup analyses
  • Randomized Phase 3 study of pomalidomide cyclophosphamide dexamethasone versus pomalidomide dexamethasone in relapse or refractory myeloma: an Asian Myeloma Network study (AMN003)
  • (no title)
  • The risk of second primary malignancies in patients receiving T-cell directed therapies for multiple myeloma: a systematic review
  • (no title)
  • Impact of residual clonal plasma cells in S-phase at the time of autologous stem cell transplantation on clinical outcomes
  • (no title)
  • Efficacy and toxicity of treatment of smoldering multiple myeloma: a systematic review and meta-analysis
  • (no title)
  • Facebook
  • X
  • Instagram
©2016-2025 MYELOMA360 & Connect BioMed
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking “Accept”, you consent to the use of ALL the cookies.
Do not sell my personal information.
SettingsAccept
Privacy & Cookies Policy

Privacy Overview

This website uses cookies to improve your experience while you navigate through the website. Out of these cookies, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may have an effect on your browsing experience.
Necessary
Always Enabled
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Non-necessary
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.
SAVE & ACCEPT